These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Gabapentinoids Increase the Potency of Fentanyl and Heroin and Decrease the Potency of Naloxone to Antagonize Fentanyl and Heroin in Rats Discriminating Fentanyl. Hiranita T; Flynn SM; Grisham AK; Mijares AE; Murphy EN; France CP J Pharmacol Exp Ther; 2024 Oct; 391(2):317-334. PubMed ID: 39179416 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the Discriminative Stimulus Effects of Binary Mixtures of Flynn SM; France CP J Pharmacol Exp Ther; 2022 Mar; 380(3):171-179. PubMed ID: 34903563 [TBL] [Abstract][Full Text] [Related]
5. Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats. Jimenez VM; Castaneda G; France CP J Pharmacol Exp Ther; 2021 Apr; 377(1):29-38. PubMed ID: 33431611 [TBL] [Abstract][Full Text] [Related]
6. Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments. Miner NB; Schutzer WE; Zarnegarnia Y; Janowsky A; Torralva R Drug Alcohol Depend; 2021 Oct; 227():108974. PubMed ID: 34492557 [TBL] [Abstract][Full Text] [Related]
7. Attenuation of the Positive-Reinforcing Effects of Ultra-Potent Fentanyl Analogs, Along with Those of Fentanyl and Heroin, During Daily Treatment with Methocinnamox in Rhesus Monkeys. Gerak LR; France CP J Pharmacol Exp Ther; 2023 Mar; 384(3):363-371. PubMed ID: 36575032 [TBL] [Abstract][Full Text] [Related]
8. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Dahan A; Franko TS; Carroll JW; Craig DS; Crow C; Galinkin JL; Garrity JC; Peterson J; Rausch DB Front Public Health; 2024; 12():1346109. PubMed ID: 38481848 [TBL] [Abstract][Full Text] [Related]
9. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. Bell A; Bennett AS; Jones TS; Doe-Simkins M; Williams LD Subst Abus; 2019; 40(1):52-55. PubMed ID: 29558283 [No Abstract] [Full Text] [Related]
10. Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity. Baehr CA; Wu MM; Pandit SG; Arias-Umana J; AuCoin D; Pravetoni M J Pharmacol Exp Ther; 2022 May; 381(2):129-136. PubMed ID: 35153198 [TBL] [Abstract][Full Text] [Related]
11. Signals of increasing co-use of stimulants and opioids from online drug forum data. Sarker A; Al-Garadi MA; Ge Y; Nataraj N; Jones CM; Sumner SA Harm Reduct J; 2022 May; 19(1):51. PubMed ID: 35614501 [TBL] [Abstract][Full Text] [Related]
12. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl. Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760 [TBL] [Abstract][Full Text] [Related]
13. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Fairbairn N; Coffin PO; Walley AY Int J Drug Policy; 2017 Aug; 46():172-179. PubMed ID: 28687187 [TBL] [Abstract][Full Text] [Related]
14. Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys. Weed PF; Gerak LR; France CP Eur J Pharmacol; 2018 Aug; 833():94-99. PubMed ID: 29807027 [TBL] [Abstract][Full Text] [Related]
15. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review. Moe J; Godwin J; Purssell R; O'Sullivan F; Hau JP; Purssell E; Curran J; Doyle-Waters MM; Brasher PMA; Buxton JA; Hohl CM CJEM; 2020 Mar; 22(2):178-186. PubMed ID: 31955714 [TBL] [Abstract][Full Text] [Related]
16. Effects of Gabapentinoids on Heroin-Induced Ventilatory Depression and Reversal by Naloxone. Flynn SM; France CP ACS Pharmacol Transl Sci; 2023 Apr; 6(4):519-525. PubMed ID: 37082751 [TBL] [Abstract][Full Text] [Related]
17. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372 [TBL] [Abstract][Full Text] [Related]
18. Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. Roxburgh A; Hall WD; Gisev N; Degenhardt L Drug Alcohol Depend; 2019 Dec; 205():107533. PubMed ID: 31704378 [TBL] [Abstract][Full Text] [Related]
19. The influence of transformations in supply on methamphetamine initiation among people injecting opioids in the United States. Mars S; Ondocsin J; Holm N; Ciccarone D Harm Reduct J; 2024 Mar; 21(1):57. PubMed ID: 38443903 [TBL] [Abstract][Full Text] [Related]
20. Heroin- and Fentanyl-Induced Respiratory Depression in a Rat Plethysmography Model: Potency, Tolerance, and Sex Differences. Marchette RCN; Carlson ER; Frye EV; Hastings LE; Vendruscolo JCM; Mejias-Torres G; Lewis SJ; Hampson A; Volkow ND; Vendruscolo LF; Koob GF J Pharmacol Exp Ther; 2023 May; 385(2):117-134. PubMed ID: 36828628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]